Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Compoundingselankbowery clinictelehealthfda category 2anxiety

Bowery Clinic expands physician-led selank program for US patients

The telehealth clinic's own overview concedes selank is not FDA-approved and that its evidence base is mostly Russian preclinical work and small trials.

MH
By Maren Holt · Senior Reporter, GLP-1
Sep 4 11:10 ETSource: rutlandherald.com

The wire

  1. 01Bowery Clinic said it expanded its selank program for eligible US patients, publishing an overview of the tuftsin-derived heptapeptide TKPRPGP marketed for stress, anxiety and cognitive support.
  2. 02Selank has no FDA approval; the clinic notes its removal from the FDA Category 2 list reflected a withdrawn bulk substance nomination, not clearance for compounding.
  3. 03Cited human data are limited to studies of 62 and 60 patients comparing selank with medazepam and phenazepam; the item is a company release, not independent evidence.

From the source

Bowery Clinic Expands Physician-Guided Peptide Program With In-Depth Look at Selank, a Synthetic Peptide Studied for Stress, Anxiety, and Cognitive Support

Bowery Clinic Expands Physician-Guided Peptide Program With In-Depth Look at Selank, a Synthetic Peptide Studied for Stress, Anxiety, and Cognitive Support / Source: Bowery Clinic

Read at rutlandherald.com